Every year, 2 or 3 stocks with a special V ticker appear on the market for less than 2 weeks... are removed... and produce double-to triple-digit returns.
| IMAV........................3,249% | EWV.............................374% |
| EYEV...........................482% | VSEAV........................562% |
| VARIV.........................502% | BSLNV........................354% |
| AGNV .......................2,221% | CRAV..........................3,139% |
Dear Reader,
It's one of the biggest phenomenon of the investing world...
Two or three times a year, a stock will appear on the market with a V at the end of its ticker... disappear 10 days later... and climb straight up.
In most cases these V stocks have returned up to 200% or better...
In fact – since 1998, these so-called V stocks have produced an average gain of 692%. The smallest gain: 36%. The biggest: 3,249%.
Even more incredible: According to our research we've ONLY found 23 V stocks that have surfaced in the last 11 years. That's less than .01% of all publicly traded stocks in that time...
And let me be clear: V stocks are not junk bonds... options... or any other risky investment. Quite simply: They emerge on standard stock exchanges... and are just as easy to buy and sell as any other security.
But the difference is: We've found that these extremely rare stocks have produced double and triple-digit gains every single time they've been made available to the public.
(The last V stock we spotted in July has since returned 114%. Ticker: FACTV)
In fact, as you're about to see – every single "V" stock that we've come across over the last decade has made money. The gains are simply incredible...
- IMAV, for example, could have turned every $5,000 into $167,480.
- Or consider CRAV, another "V stock." It was only available for less than 10 days before it disappeared... but ended up returning ,139%.
In short: The newest V stock has just appeared on the market...
It emerged onto the New York Stock Exchange recently at about 9:30 a.m. and is being offered by a small technology firm in California.
Bear in mind: Only a few announcements about this stock were made available to the public. But this was NOT an IPO. In fact: About 90% of the investing world has no idea this stock even exists...
But if you follow our instruction, this single event could create the biggest gain you see this year – a quick 50% over the next few months and a 200% return in the long run even though this V stock has already disappeared.
Let me give you the full story...
When we first discovered the V stock phenomenon, we didn't believe it...
For one thing – all the V stocks we've found over the past decade have a winning record... we couldn't find a single loss.
Secondly – every V stock we've spotted since 1998 has produced double- to triple- digit gains. In many cases, the returns exceeded 200%...
The most intriguing part was this:
Without fail... these V tickers DISAPPEARED within just 10 days of appearing on the market. After that, you never see them again.
Take Hospira, for example, a hospital management company. At a glance, you'd probably never guess this no-name firm from the sticks of Illinois could do anything for you...
But in May 2004... a V stock appeared on the market – HSP"V" – which was later traced to Hospira's CEO. Sure enough – within 10 days, the ticker disappeared from the market. GONE... in the snap of your fingers.
Yet if you were fortunate enough to take advantage of this situation you could have made a 95% return... even after it had disappeared.
Or consider Celera Corp. In April 1999, the ticker CRAV appeared on the market, traceable to this California tech firm – for about $7 a share.
It traded for about 10 days...
Then, on the morning of May 5th, it simply disappeared. The ticker was removed from the market... and could no longer be bought.
 |
But if you found it in time, you could have watched this $7 share jump to $242 a share, a 3,139% gain. |
To put that in perspective: Every $5,000 stake turned into just over $160,000... on a single stock.
But these kinds of gains are typical with V stocks. Here's just a snapshot of what we found in our research... along with the investment return:
| AGNV........2,221% return | IDIXV..........194% return |
| PMCV.......87% return | WBMDV..... 152% return |
| IMAV........3,249% return | EWV............374% return |
| TRGTV......209% return | PMBSV........150% return |
Notice how each ticker ends in the letter "V."
In some rare cases, the V did not appear. You see – because these stocks disappear after 10 days, there's no accurate way to track every single one and, occasionally, market makers will use a different letter. But this makes no difference and has no bearing on the performance of the stock.
Other than this single identifier, these companies have very little in common. If it weren't for the V... you'd probably never even find these unusual stocks.
They'd be buried under the thousands of other publicly traded companies on the U.S. exchanges... practically invisible...
But as I'll explain: By working closely with a professional trader, (who's followed this phenomenon successfully for the past 2 years), we now know exactly what to look for... and how to "catch" these stocks the moment they disappear.
As I mentioned: The newest V stock has just emerged on the NYSE... and could easily return 200% or more.
The only catch: This opportunity won't be around for long...
Now before I continue, and give you all the specifics of this opportunity... I need to make something clear...
In short: V stocks are not IPOs.
As I'm sure you know: stocks don't just magically appear on the market. They normally "go public" as an IPO... through an issuing by a Wall Street bank.
But as you're about to see: The V stock phenomenon we've descovered has nothing to do with that process... and is NOT an "initial public offering."
As a rare article on this topic in Kiplinger's says: "In direct contrast to IPO's, there are no investment bankers to profit from [these stocks]. Analysts... ignore [them]."
Or consider BusinessWeek – who wrote one of the few studies we've seen about this phenomenon in the mainstream media:
"Wall Street isn't paid to tout these stocks, so they initially tend to fall through the cracks."As a result, most people (like you and me) never hear about these stocks – for the simple reason that they appear almost completely unannounced with none of the fanfare that surrounds IPO's...
The good news is: There's a secret to spotting these opportunities...
In short – when companies offer a V stock... they bypass Wall Street and only appear in a temporary niche of the market, typically denoted by the letter "V."
For example, take Varian Semiconductor Equipment Associates.
In the late 1990s – this California-based supplier made millions in profit, selling X-ray machines. To medical insiders, the firm had a bright future...
But on April 5, 1999, when the company offered a V stock on the market, there was no official announcement... and zero press coverage.
Instead, through a unique decision by the CEO (more on this below)... the stock was assigned to an obscure niche of the stock market, with the ticker: VSEA"V."
Within 10 days, it was removed. But overall, it returned 562%.
- The same thing happened to Basilea... When this successful manufacturer offered investment shares... the CEO assigned it to the V niche.
- Or consider APP Pharmaceuticals. When this Illinois firm offered shares in February 2008, it was assigned ticker APPX "V." Return: 150%.
Its ticker – BSLN V – disappeared in 10 days. Return: 354%.
As you know – a stock ticker has just one purpose: to identify a company. When a broker makes a transaction, he uses the ticker to execute each new trade...
Well, in this case – not only does the ticker identify the company, it also assigns it to a virtually unknown part of the stock market... known as the V niche.
But let it be clear: This is not an options market or a futures exchange.
The V niche is a temporary holding place within the regular stock market for a handful of companies that want to raise capital... without going through the hassle of offering a traditional IPO.Of course – unless you know how to access this niche market... you'd never know how to find these companies. As I said earlier, their tickers only list for about 10 DAYS (sometimes even less) before being removed.
But if you catch them early enough... these fleeting opportunities could produce double- to triple-digit investment returns, as they have in all 23 cases we've found over the past 11 years.
So exactly how does this phenomenon work?
To make a long story short: V stocks are made available for a limited-time by CEOs... who want to bypass Wall Street and raise capital for their firm.
And as these stocks continue to outperform the market, companies from various industries are now issuing these V stocks.
Take HSN Inc, for example – the Home Shopping Network...
HSN's CEO, Mindy Grossman, is the exact opposite of a typical Wall Street CEO. She began her career working for clothing companies, studied English Literature at Manhattanville College... and Philosophy at George Washington University.
In other words, she's probably the "hippie-dippie" type – freethinking and non-business-like. The exact opposite of a Wall Street banker.
It's no wonder, then – that last August... when Grossman wanted to raise capital for HSN... she decided to bypass Wall Street and instead offer a V stock.
The result: If you'd gotten in at the optimal buy point, you could have made a potential 802% gain.
Or consider CEO Rick Whiting, who runs the third largest producer and marketer of coal in the United States: Patriot Coal Corporation.
He was born in West Virginia, and studied to be a mining engineer...
As you can imagine, Rick is the last guy you'd find sitting in a glitzy office sipping a latte in a $5,000 suit.
So in October 2007, when Rick was looking for a way to grow his business and raise money, he offered a V stock instead of a traditional IPO. The result: you could have made a 464% return by getting in.
You see – typically CEOs fork out hundreds of thousands of dollars in accounting and legal fees to register their company for an IPO. In addition, the SEC rules for taking a company public are so elaborate, most CEOs are forced to hire expensive experts to handle all the paperwork. It's a complete hassle.
But by offering V stocks, CEOs like Rick Whiting and Mindy Grossman are able to easily bypass these hurdles.
In other words, V stocks have not only shown incredible returns for regular investors, they also offer an effective way for a small-time CEO to raise capital and grow their business.
And get this: Historically, V stocks have outperformed the market by an unbelievable margin. Take a look:
- Two accounting professors from Southern Methodist University and Tulane University confirmed that V stocks beat other stocks by as much as 36.2%. The McKinsey Quarterly Business Journal and The Journal of Financial Economics reached similar conclusions.
- Over a 40-year period, two business professors at Penn State University tracked every V stock to hit the market and found that on average these stocks generated 51% gains in the first two years and 106% in the first three years of trading.
- In a study conducted between 2000 and 2005, a financial service firm out of New York found that V stocks beat the S&P 500 by an average of 45% in their first two years as publicly traded companies.
Let me explain...
Every year, around 40 V stocks appear on the market... in every sector available...
But it just so happens that in one particular sector – only 2 to 3 appear in a single year. And the track record, including all the stocks we've found over the past 11 years in this sector, is flawless: 23 for 23. Not a single loss among them.
That sector is healthcare.
You see, in healthcare... there are a variety of different firms, from tiny biotechs and startup medical suppliers to Blue Chip drug makers. And we've learned that in the past 11 years, every single healthcare V stock we found has been a success.
In fact, if you'd put $5,000 into each of these 23 healthcare V stocks, you'd have potentially made over $795,750 in PURE PROFIT on these 23 stocks alone...
That's almost a million dollars in gains.
And that's why the V stocks we focus on (many of which appear in the examples I'm sharing in this letter) belong to this single phenomenal sector.
Of course, this doesn't mean that V stocks in other sectors of the market haven't produced exceptional gains. A few moments ago you saw HSN and Patriot Coal, both of which are V stocks that were not offered by healthcare companies.
| • | Or take Conexant Systems for example. On Jan. 4, 1999, this semiconductor company offered a V stock for $74 a share. The ticker: CNXT"V." Just ten days later the ticker symbol disappeared... but returned a 1,454% total gain. |
| • | Or consider Atlas America, an oil and gas producer in Pennsylvania. The company offered a V stock (ATLSV) on May 12, 2004 - and the ticker was removed a week later. Yet investors who knew about it could have made a 669% gain. |
| • | Or look at Equifax Inc., which collects and manages financial marketing information. The company's V stock: EFXV was offered at $5 a share and eventually shot up to $45. That's an 800% gain. |
But in healthcare, V stocks have offered what we believe are the most consistent, rare, and successful winners. Again: only 2 to 3 appear each year...
That's why we recently spoke with Dr. George Huang, a Ph.D. medical analyst.
Dr. Huang has spent the last decade working in the country's #1 most prestigious medical institutions... like Johns Hopkins University and the bioinformatics firm Helios based out of Vancouver.
He's on a first-name basis with dozens of healthcare CEOs...medical specialists... and practicing doctors around America.
As Dr. Huang recently found, the newest V stock just hit the healthcare sector on September 1. And unlike most stocks of its kind, this one has an unusual twist, which could make it more profitable than any that we've seen.
Here's why...
In short: Earlier this month, on Tuesday, September 1, a new V stock appeared in the healthcare sector...
A medical firm that makes hospital equipment issued it. They sell tens of dozens of healthcare products in 120 countries... from surgical instruments to respiratory machines... and are expected to make $4 billion next year.
But the reality is, we couldn't care less how much the firm will make. To you and me, there's just one thing that truly matters about this situation...
In a nutshell: It's 1 of just 3 healthcare V stocks to appear so far in 2009.
And if the past decade is any indication... its shares could easily rise by at least 200% in the coming months, potentially even more.
|
As I said before: Earlier in the year, we found a V stock in healthcare and recommended it. Within a few months, it returned 114%.
And it gets even better...
Not only has this company just offered a V stock... but it just joined the S&P 500, which means the potential return could be simply enormous.
Believe me, this is extremely rare. Most V stocks are small and unknown... issued by companies you'd be embarrassed to even talk about on the golf course or at a cocktail partu.
But the fact is, this medical firm from California has just joined the list of America's biggest and most profitable firms.
And the CEO publicly said in a recent statement: "Our inclusion in the S&P 500 is a testament to our position in the industry."
But by now you might be wondering: "How do I invest in this stock? Don't these V stocks disappear within 10 days... never to be seen again?"
Well, that's where this opportunity gets even more interesting...
As I'm sure you know, a stock ticker usually only disappears from the market if a company goes out of business... or is bought out.
But when a V stock disappears from the market... it simply marks a transitional period... which requires it to be REMOVED from the V niche... and listed on the regular stock exchange.
And when that happens – the V is removed from the end of the ticker... and the firm continues to trade under a brand-new stock ticker.
Here are just a few examples...
| V Ticker |
New Ticker |
Return |
AIZV |
AIZ |
178% |
MGIV |
MGI |
117% |
BWPV |
BWP |
114% |
Notice how the V disappears from the ticker, every single time.
It sounds bizarre, I know. And it is. That's what makes this one of the least-known market phenomenon in the world.
But the reason behind this is: Companies can only trade in the V niche for approximately 10 days. After that, the stock is required to take its place next to the 1,000s of other public companies on the market.
When that happens, the V is removed from its ticker symbol.
It's that simple.
That's how companies like HSN... Patriot Coal... and the other examples you've seen were able to bypass the IPO process.
So the big question is: Why have we been making such a big deal about this V if it simply disappears from a company's ticker after 10 days?
In short, Dr. Huang has discovered that as soon as the V drops from the ticker... the stocks often goes through phases... then suddenly skyrocket.
In essence: You make the potentially largest gains from this phenomenon by carefully tracking the V stock from the moment it appears in the V niche... to the moment it disappears... and enters the regular markets.
But most investors have no clue how to spot the best time to buy and sell these stocks.
You see we found that V stocks follow certain patterns, in large part because big institutions are required by their charters to take certain actions when these stocks first appear.
We've also discovered that the optimal buying point is 30-60 days after issue, from which point these stocks go straight up for an extended period of time.
In the examples we've shared with you in this letter, the gains were calculated based on these optimal buy and sell points of the V stock, because this is what Dr. Huang uses when looking for the greatest upside potential.
As you're about to see, Dr. Huang only looks to recommend these stocks at a very precise moment... and he doesn't just hold onto these stocks forever. This is why we've demonstrated the results this way in this letter.
Take World Poker Tour Enterprises, for example.
On August 10, 2004, a V stock appeared from this firm with the ticker: WPTE "V." After 10 days of trading in the V niche, it was removed and listed on the NASDAQ under the new ticker WPTE.
|
Same stock ticker...without the "V." |
Why is this important? Because if you had spotted it early enough and bought the stock soon after it hit the NASDAQ and sold at the right moment, you could have made a 278% gain - enough to almost quadruple your money.
The same thing happened to Kronos Worldwide Inc.
Kronos' CEO, Harold Simmons, chose to make a V stock available on Dec. 9, 2003 with the ticker: KRO"V."
Within 10 days, it was trading on the NYSE... under a new ticker: KRO.
Again: Same stock ticker... without the "V." And if you had bought this stock as soon as it hit the market and sold it a year later you could have made a 172% gain.
So how exactly does Dr. Huang pinpoint the best time to get into these stocks?
The truth is, every company that issues a V stock is required to submit a certain document to the U.S. Securities and Exchange Commission.
This 4-page form, known as a Form-10 registration statement, provides the SEC with full details of the upcoming V stock release, including everything from the company's financial statistics to a list of its directors and executive officers.
To most people, the information on this form is totally meaningless.
But since 2007, Dr. Huang has been using Form-10 in a way that nobody else in America (as far as I know) has been doing, to spot these opportunities...
In a nutshell: By analyzing over a decade's worth of Form 10 data... in addition to the medical research behind each new company... Dr. Huang has created a single indicator allowing him not only to spot V stocks – but also to pinpoint the best time to buy and sell them on the regular markets, for the biggest and fastest return.
It's one of the newest and most unusual trading strategies we've developed here at S&A Research, and is already showing our subscribers a killing.
As I said earlier, the last V stock Dr. Huang found in July has already returned a 114% gain... and it isn't showing any signs of slowing down.
But understand... Form-10 isn't easy to find.
You see, as I said before: V stocks don't have IPO's... so you're not going to hear about them from your broker or see them on CNN.
Furthermore, most large institutional investors like mutual funds and portfolio managers, aren't allowed to own V stocks because they're typically too small.
As a result, they're almost completely overlooked by mainstream investors and the media.
That's why Dr. Huang's Form 10 trading indicator is the only way we know of to consistently spot these phenomenal stocks.
But you don't have to know anything about Form 10...
Because the fact is, the only thing that truly matters is this: Right now, according to Dr. Huang, the newest V stock is poised to take off at any moment.
We only became aware of this phenomenon in July, when he recommended a V stock from Redwood City, California.
In less than 3 months, it more than doubled.
When Dr. Huang explained the phenomenon, we asked him to write a special report, outlining exactly how it works... so we could make it available for any S&A subscriber who wants it.
His new report: The V Stock Phenomenon, is now available online, and you can access it right now – in the next 5 minutes – at no charge.
Inside, you'll learn:
- The NEWEST V stock, which Dr. Huang believes could return 200%... and, he says, "you should get in as soon as you possibly can."
- How V stocks appear and disappear in the market
- When to get in for the biggest and fastest potential returns
So he walked us through dozens of examples... and explained exactly how these V stocks work, from release... to disappearance... to total return.
Over the past 11 weeks... we've found dozens of V stocks offered by companies in recent years. And every single case validated Dr. Huang's indicator.
| V Stocks: | Total Return: |
| Mosaic Co. | 1,000% in 3 years |
| Avaya | 815% in 5 years |
| Ormat Technologies | 258% in 2.5 years |
| John Bean Technologies | 223% in 9 months |
| Alon USA Energy Inc. | 160% in 1.8 years |
| Brinks Home Security | 121% in 9 months |
| VMWARE Inc | 125% in 74 days |
But what surprised us most of all was how well V stocks have performed in the healthcare sector...
Again : Every V stock we found that was made available by a healthcare firm since 1998 has produced double- and triple-digit gains, without fail. Not a single loss.
And as it turns out, we're not the only financial detectives to discover this. Although rarely mentioned in the mainstream press, a small handful of stock market analysts and academics have also discovered the benefits of V stocks:
- Amateur financial reporter Andy Leland writes: V stocks are "largely ignored by Wall Street... yet often prosper under their own power, going on to post big gains."
- And a CFA from Boston states: Companies offering V stocks "are amongst the least-followed potentially lucrative investments available."
And so far, Dr. Huang has found all of them in 2009. The first is a healthcare company out of Alameda, CA that expects to generate about $165 million in revenue this year.
The second comes from a small biotech firm out of Salt Lake City, UT. It's currently trading for less than $7 a share and is set to partner in a deal worth more than half a billion dollars by years end.
And the third is a biotech stock based in San Diego... which just appeared on September 1st... and like the others, will be outlined in full in Dr. Huang's newest report.
It all boils down to the most unusual trading research we publish...
When Dr. Huang first approached us in 2008, we were puzzled...
He had just spent the past 5 years at America's top medical school... conducting drug and vaccine research that's been published in some of the most prestigious medical journals in the field like American Journal of Physiology and Molecular Biotechnology.
We wondered, "Why would a Ph.D. medical analyst be interested in working for an investment research firm?"
But Dr. Huang surprised us. Because after a full background check – we hired him... and set him loose to create one of the most successful research letters we've ever published, in 10 years in the business...
It's called The S&A FDA Report.
Focused on quick-moving trading opportunities in the medical field, Dr. Huang's research uses his academic background (and contacts in the industry) to uncover some of the least-known and most profitable opportunities in the market... like the V stock phenomenon.
Quite simply: The FDA Report pinpoints the hundreds of "inefficiencies"... "glitches"... and "anomalies" that exist in the medical sector... as a single investment strategy.
How successful has Dr. Huang been? Well, since he began, he's produced one of the best track records of any advisory letter in S&A history:
In 2009 alone, Dr. Huang has shown his readers 13 double-digit winners.Consider...
Last fall, during the financial collapse, while most investors were losing their shirts, Dr. Huang discovered a pricing "anomaly" in the medical sector that showed his readers 88% gains in 14 days with a company called Intermune (ITMN)... and 105% gains in just 7 weeks, with the drug maker Dendreon (DNDN).Of course, what really matters is what his subscribers are saying...
Soon after, Dr. Huang uncovered a regulatory "loophole" in the Food & Drug Administration's (FDA) drug approval process. Readers who followed his advice saw 49% gains in 3 months (on ViroPharma) and 74% gains in 6 months (on Indevus).
And recently, in Feb. 2009, Dr. Huang uncovered a rare buyout situation in the medical sector involving a Dutch vaccine maker and one of America's largest healthcare companies. Readers who have taken advantage of this situation have seen a 100% gain in 7 months (as of Sept. 2009).
"I made 299% on SSPI! Thanks for another FDA winner!"In short: When it comes to the medical sector, Dr. Huang has found a way to make money with just about every situation you can imagine... drug approvals... buyouts... even failed drugs.
J.M., Sullivan, NJ
"I've been trading stocks for about 35 years and subscribe to 5 different newsletters. The FDA Report is the only one that has consistently made me money in the past year. I've made 100% on IDEV, 160% on SPPI, 25% on DYAX, and 40% on DNDN... Obviously, I'm very pleased with the results."
R.R., Chesapeake, VA
"It's been fun following your picks... I made 70% in 4 weeks with Intermune!"
P.S., Lancaster, PA
Let me show you what I mean...
Last December, during one of the worst years in biotech, Dr. Huang told his readers about a tiny firm in Vancouver called QLT.
At the time, it was trading for just $2 a share.
There was nothing exciting about this firm. It didn't have a new miracle drug waiting for FDA approval... a research break-through... or any upcoming partnerships. To most people, it was a loser.
But when Dr. Huang analyzed the company's science and background, he discovered this little-known biotech firm receives royalty payments on two marketed drugs that together generate $350 million in sales per year.
He immediately recommended the stock to his FDA Report readers, writing: "I expect to book at least 100%-200% on this play."
Sure enough, just seven months later... the stock shot up 101%, and continues to rise even now.
But that's just one example of what Dr. Huang uncovers...
In The FDA Report, Dr. Huang frequently uses his business contacts to show his readers the best opportunities...
Last September, something unusual happened to Dr. Huang...
In the space of just 30 days – 2 companies he'd recommended in The FDA Report were BOUGHT OUT...
The first: When Eli Lilly announced an offer to buy Imclone, a vaccine maker, for $70 a share. Dr. Huang's readers saw a 60% gain.
The second time: When King Pharmaceuticals announced an offer to buy Alpharma, a drug maker, for $37 a share. Again: FDA readers who followed Dr. Huang could have made a double-digit gain: 83% in 60 days.
Of course, it's no secret that stock buyouts are one of the best ways to make money in the financial markets....
But somehow... Dr. Huang had solved the most difficult problem with these situations: predicting WHICH stocks will be bought... and which stocks will not. Often, it's a total guessing game...
But in March, he did it again...
Swiss drug maker Roche bought the San Francisco-based biotech firm Genentech for $89 per share, and Dr. Huang showed his subscribers a 99% gain in 5 months on the situation.
More recently – in May 2009, Dr. Huang spotted two more buyouts in the medical sector...
Pfizer's purchase of big pharma player Wyeth (WYE)... and Merck's of Schering-Plough (SGP) – both of which have returned over 40%... and are still climbing fast.
As Dr. Huang says: "I think everyone knows there's big money to be made in buyouts. The problem is, it's typically corporate insiders who pocket all the gains."
Well, fortunately, Dr. Huang has found a market "anomaly" in a tiny sub-sector of the markets that allows regular people to predict – sometimes to the very hour – these lucrative buyouts.
FDA Report subscribers have made a fortune...
"Dr. Huang, great call on Genentech... I pocketed $22,000!"And that's not all...
J.R., Stanford, Ca
"It's been a bit over a year now and I have to say that the results have been nothing short of spectacular, especially compared to what the overall market has done over the past year... I made 190% with IDEV and 200% with SPPI."
H.C., Chelmsford, MA
Dr. Huang has even found a way to make money on FAILED drugs!
I'm sure I don't have to tell you that one of the most profitable things you can do in America is develop a new drug to treat a debilitating disease.
The rewards are simply staggering...
Did you know, for example, that drug companies can charge about $20,000 per year for a single successful drug? It's no wonder blockbuster drug makers go from penny stocks to household names.
But what most investors don't know is that you can make a fortune every time a new drug FAILS. And because new drugs fail 80% of the time... well... you could make an absolute fortune on these situations, often overnight.
In fact, it's a secret Dr. Huang has used personally, in his own trading account, to predictably and consistently make a killing in the pharmaceutical industry:
For example, not too long ago, a company called Introgen began touting their new cancer drug, Advexin. Shares of Introgen topped $3 as mainstream investors bought shares left and right.And then...
But after investigating the company... and the science behind the drug... Dr. Huang discovered the drug could never work. When it failed at the FDA, Dr. Huang made 80% as the stock crashed.
Several months ago, a company called Electro-Optical Sciences (MELA) began developing a device to screen for skin cancer. Anticipation of the trial results pushed the stock to almost $10. Again, investors got excited... but Dr. Huang knew the device would never make it past the FDA. Sure enough, he made a quick 60% profit.These opportunities are everywhere. You just have to know where to find them.
And after spending years working in the biotech sector alongside the scientists and doctors behind clinical drug trials, Dr. Huang knows exactly what to look for.
In July 2009, for example, Dr. Huang noticed Osiris Therapeutics (OSIR), whose stem-cell drug is set to FAIL its Phase III trials at the FDA this month.
By recommending a unique play to take advantage of this situation, Dr. Huang has already shown his readers a 59% gain.
Believe me, nothing quite like Dr. Huang's FDA Report advisory newsletter exists anywhere in the financial world.
No matter what the situation – new drug approval... failed drug trial... buyout... even a stock phenomenon like the one I've been sharing with you in this letter – his readers consistently see huge returns.
As FDA subscriber Joseph Menth writes: "I have been giving FDA teasers to a friend at work, but up till last week he hadn't made a move on any S&A newsletter. But when I crowed to him about closing an FDA pick for 413%, I had his attention. When I added that the only other FDA pick I had closed this year did 198%, he asked for a link and signed up that day."
However, before I go any further... let me make something clear:
If you're only interested in taking a "buy-and-hold" approach to your investing, The FDA Report may not be right for you. It's not meant for amateurs.
Dr. Huang uses a trading strategy, focusing only on opportunities that offer abnormally quick returns... in a matter of weeks, sometimes, even days.
So if you've never bought an option or shorted a stock before, and never intend to, then I suggest you look elsewhere.
Every play Dr. Huang recommends is clearly outlined and explained in a simple, step-by-step manner, so you understand exactly what to do.
FDA Report subscriber Dan Quartin agrees: "Even a layperson can understand what's going on. Thanks for the great picks and insightful commentary."
|
Well, in the past, we've charged $5,000 a year for similar research. We think that's a bargain, considering the hours of work that goes into this report, every month.
(Every year, Dr. Huang logs hundreds of air-miles attending conferences like the Biocentury newsmakers conference and Future Leaders in Biotech conference, both held annually in NYC.
He also attends exclusive gatherings for scientists including the Bioinvestor Forum in San Francisco and the Keystone Symposium in Whistler, Canada... to meet with the CEOs of biotech firms... and speak directly to the scientists who are involved with some of today's top medical break-throughs.)
The price for one full year of FDA Report is $2,400.
But, beginning right now and ending shortly, we're going to make it even easier for you to give this research letter a try...
We're offering The FDA Report for HALF-OFF the regular rate.
In other words: Get in before this offer expires... and you can receive one full year of The FDA Report for just $1,200. That's a 50% discount.
Even better, we'll then give you 90 DAYS to decide whether or not Dr. Huang's research is right for you. If it's not... of if you're unhappy for any reason... no problem. Just let us know. We'll give you a refund minus a small 10% refund fee (see order form for more details).
Personally, I think getting The FDA Report for $2,400 a year is a bargain, considering that just one of his recommendations could help you make 10 times that amount (see what subscribers are saying below).
But getting it for just $1,200 is a steal. Consider:
Made more than enough to pay for the subscription price!The fact is –you could easily make back the entire subscription cost on your very first play... the V stock you'll learn about in Dr. Huang's newest report: The V Stock Phenomenon.
"I made 186% gains on Indevus. The profit was more than enough to pay for another year of FDA, so I called your office yesterday to renew. With each profitable trade, my confidence gains in Dr. Huang's insights and analysis of the biotech arena. I'm expecting even better returns from FDA in the coming year."
H.C., Spartansburg, SC
One pick paid for the subscription!
"I have made some quite spectacular gains... the Spectrum trade alone paid for my subscription cost!"
M.M., Cherry Hill, NJ
And get this...
If you had invested $5,000 into just five of Dr. Huang's top recommendations this year, you could now have $53,075.
As FDA Report subscriber Bob Jessheim writes: "I bought QLTI and made more than 100% in less than 2 months. This more than pays for the subscription. Most (if not all) your stock picks have been home runs. Remarkable!"
When you become a new Member of The S&A FDA Report, you'll immediately begin receiving Dr. Huang's monthly trading research reports... the kind of picks that have returned:
- 105% in 2 months
- 160% in 1 month
- 88% in 15 days
Special Report: The V Stock Phenomenon. This members-only report details Dr. Huang's newest V stock recommendation, along with full details on two additional V stocks from this year. You'll learn exactly how to buy these stocks... Dr. Huang's proprietary strategy for finding them... and why the most recent one (which he recommends you buy immediately) could make you 200% or more.What it comes down to is this...
FDA Report Trading Primer: This special, members-only report will explain everything you need to know about Dr. Huang's trading strategy. Read it right away, before you review anything else. You'll learn the full details behind Dr. Huang's approach to making money "at the hands" of the FDA, including many interesting techniques I didn't have time to explain in this letter. You'll also learn about Dr. Huang's timing indicator, which helps predict the PRECISE time to pull the trigger on each new play
FDA Report Monthly Issues: Every month, Dr. Huang will send you a new report – detailing the most recent trading opportunity he's found in the medical sector. Depending on what he sees, Dr. Huang will often recommend up to 2 to 4 new plays per issue.
FDA Report Trading Alerts: Throughout the month, Dr. Huang will keep you posted by email on every single play he recommends, as necessary. Use these alerts to optimize your gains and see even bigger returns with Dr. Huang's recommended portfolio.
The medical sector is overloaded with "glitches"... "anomalies" and "stock phenomena" that could make you a fortune, if you know how to spot them in time.
By following Dr. Huang, you'll know about each of these opportunities in advance... while 99% of the market does nothing.
The opportunities are there. It's up to you to grab them.
To get started, Subscribe Now
Sincerely,
George Rayburn
Publisher, Stansberry & Associates
September 2009
P.S. Don't forget... you can get HALF-OFF the regular rate. But only until this offer expires. See the order form for more details.